- Home
- HPP vs AURA Comparison
HPP vs AURA Comparison
Compare HPP & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- AURA
- Stock Information
- Founded
- HPP 2009
- AURA 2007
- Country
- HPP United States
- AURA United States
- Employees
- HPP N/A
- AURA N/A
- Industry
- HPP Real Estate
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- AURA Health Care
- Exchange
- HPP Nasdaq
- AURA Nasdaq
- Market Cap
- HPP 420.6M
- AURA 379.6M
- IPO Year
- HPP 2010
- AURA 2021
- Fundamental
- Price
- HPP $3.17
- AURA $7.93
- Analyst Decision
- HPP Hold
- AURA Strong Buy
- Analyst Count
- HPP 11
- AURA 4
- Target Price
- HPP $4.75
- AURA $23.00
- AVG Volume (30 Days)
- HPP 6.1M
- AURA 143.3K
- Earning Date
- HPP 02-20-2025
- AURA 11-12-2024
- Dividend Yield
- HPP 3.17%
- AURA N/A
- EPS Growth
- HPP N/A
- AURA N/A
- EPS
- HPP N/A
- AURA N/A
- Revenue
- HPP $847,713,000.00
- AURA N/A
- Revenue This Year
- HPP N/A
- AURA N/A
- Revenue Next Year
- HPP $0.04
- AURA N/A
- P/E Ratio
- HPP N/A
- AURA N/A
- Revenue Growth
- HPP N/A
- AURA N/A
- 52 Week Low
- HPP $2.39
- AURA $6.63
- 52 Week High
- HPP $9.25
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- HPP 54.13
- AURA 44.05
- Support Level
- HPP $2.84
- AURA $7.46
- Resistance Level
- HPP $3.04
- AURA $7.90
- Average True Range (ATR)
- HPP 0.19
- AURA 0.30
- MACD
- HPP 0.08
- AURA 0.02
- Stochastic Oscillator
- HPP 74.26
- AURA 47.24
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.